Our ultimate goal at Exothera is to make life-changing therapies available for all. To achieve this, our teams’ mission is to design and deliver bespoke bioproduction journeys for innovators to achieve successful market entry for their viral vector or RNA therapeutics Re-Building and energising a Global Commercial Sales and Marketing Team Successful and rapid Change Management strategy $500 million pipeline generated. Re-defining Global GTM strategy, with full ‘buy in’ from stakeholders Creating a ‘culture of collaboration’ between un-aligned Business Units and Companies. Re-awakening the passion and drive within individuals.

 Building an NA Sales and Support organisation from scratch. Successful integration of Support and Service Teams with existing Commercial Ops Re-defining Global GTM strategy and implementing. Refocussing RnD to top 10 Cancers and generating ‘Proof Statements’ as PoS Tools Leveraging KOL and Strategic Partner networks to scale revenue.

Headed up the EMEA (and subsequently Global) commercial operations for Resolve Biosciences and it's leading edge spatial transcriptomics technology : Molecular Cartography. A guy who gets things done! As opposed to the usual of .. talking about getting things done.I regard myself as more of a Life Science generalist than a content expert but still being passionate about building effective and efficient commercial organisatizations for the betterment of Human Kind. $4 million in Services revenues +20 Molecular Cartography systems placed (ASP c $500k) Building an EMEA organisation from scratch. (BDMs, ISS, FAS and FSE) De novo process development and deployment to scale the business. Inculcating mantra that ‘Good enough is not good enough’. Creating a ‘belief culture’ pan-company. Defining strategic direction of business and engineering quick wins. Creating a high EQ/MQ culture to drive Team success.

𝐂𝐫𝐞𝐚𝐭𝐢𝐯𝐞, 𝐂𝐡𝐚𝐫𝐢𝐬𝐦𝐚𝐭𝐢𝐜, 𝐓𝐫𝐚𝐧𝐬𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐋𝐞𝐚𝐝𝐞𝐫 𝐓𝐨𝐩 𝐩𝐞𝐫𝐟𝐨𝐫𝐦𝐢𝐧𝐠 𝐄𝐌𝐄𝐀 𝐑𝐞𝐠𝐢𝐨𝐧 𝐟𝐨𝐫 𝟖, 𝐜𝐨𝐧𝐬𝐞𝐜𝐮𝐭𝐢𝐯𝐞 𝐪𝐮𝐚𝐫𝐭𝐞𝐫𝐬 : 2020 to 2022 Rapid Business and Organizational Turnaround Significant double digit growth quarter on quarter under lockdown conditions Galvanizing and Transformational Strategic Leadership → 'Greater than Sum of Parts' Team creation Transformational growth across all product portfolios : 3’, 5’, Spatial Transcriptomics, CRISPr, Multiomics and instruments and automation Team transformation from MOR to Stellar performers Strategic input and guidance on Marketing Planning Planning and implementation of strategic OD to increase sales 100% by 2023 Active Talent retention and development for succession planning High profile member of Senior Leadership Team

Continuing the +ve trend of transmutational growth across UK and Nordics Leveraging Takara Bio's Innovation and Expertise Single Cell Biology  NGS and Single Cell Automation  Gene Expression  PCR and QPCR Cloning  Gene Editing  Stem Cells and Regen Medicine and  Cell and Gene Therapy +23% Organic Growth in 2018 across UK and Nordics +27% Organic Growth in 2018 across Nordics +26% Organic Growth in 2018 across UK  €1 + million de novo instrumentation sales in 2018

Working Internationally, across several business cultures to improve and develop direct sales organisations in UK and Swedish regions. Currently transforming the business at all levels while achieving significant double digit growth in a 'pure competition' Marketplace.Transformational Growth in 2012 to 2016100% CAGR in 3 years€3,000,000 new business added to top lineOutgrowing market by > 5 - 10 foldSuccessful integration of 2 new businesses in 2017 which will take our organisation forward in 2018 and beyond.

Trans-formative Business Process Improvement Services for the Life Science marketplace.

 Full P+L responsibility c $20 million. Senior member of Northern and European Management Team. Aggressive capture of market share in focus areas: Imaging and Amplification Profitable management of UK and Irish Life Science business unit for 14 years. Organisational selling efficiency through regionalised Sales Teams and Managers. Operational Manager for ISO Program: Sales Support Group (4 staff). Managing of distributor business. Key Lead on budget setting and management. Key contributor to marketing strategies. Tactical Marketing campaigns instigator. Successful integration of new business unit (Ciphergen) in 2006. Successful integration of new business unit (MJ Research) in 2005. Implementation and monitoring of annual targets and budgets. Created and developed head count for Public Sector Tenders. Hand-picked and constructed 50% new sales force in 2001 as result of expansion. Created Regional Manager Positions. Created and developed Molecular Biology Specialist roles. Key objectives and development pathway set for all Sales staff for 12-month period. Involved in implementation of new CRM. Generation of sales information for effective Account Management (weekly). Created the paper-less sales office in 1997. Orchestrating and delivering productive and motivational Sales Meetings

Coaching and Supporting a team of 4 Account Managers and 2 SpecialistsRemit involved maintaining and progressing team spirit and promoting a good working environment; supporting and motivating sales representatives at all levels.

Northern UK coverage for Capillary Electrophoresis salesAverage order value : c £40,000Specialist responsible for the sales and support of Capillary Electrophoresis. Remit encompassed lead generation and qualification, demonstrations and presentations and closing business. Unit sales increased 100% (1994 vs. 1995).

Apprentice and JourneymanScotland and NE England down to Middlesbrough (£330K – 1990; £890K- 1993).Product categories include Molecular Biology, Electrophoresis, Immuno-chemistry, Chromatography and Imaging Systems. In 1991-1993 obtained membership of The Presidents Club. This was created to reward members of the sales force who achieved sales of greater than $1 million in a calendar year. In 1992 year end target was attained in 10 months a Bio-Rad first.

R & D Lab Rat, working in Anxiolytics and Antidepression Project. In vitro, in vivo, ex vivo work on GABA-a ReceptorsCNS research project member at Harlow R & D site. Work involved screening and maintenance of Primary and Secondary drug evaluation assays as well as devising and optimising other novelscreening strategies. Techniques familiarised with included: Radio-ligand BindingAssays, Electrophoresis, Western Blotting and Chromatography.